Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 27;7(12):2731-2732.
doi: 10.1182/bloodadvances.2023010051.

Autologous transplant and second malignancies in MM

Oren Pasvolsky  1   2   3 , Qaiser Bashir  1
Affiliations
Editorial

Autologous transplant and second malignancies in MM

Oren Pasvolsky et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: Q.B. reports research funding from Acrotech Pharma, GSK, and Stemline Therapeutics. O.P. declares no competing financial interests.

Comment on

  • Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
    Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD Jr, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Ragon BK, et al. Blood Adv. 2023 Jun 27;7(12):2746-2757. doi: 10.1182/bloodadvances.2022009138. Blood Adv. 2023. PMID: 36827681 Free PMC article.

References

    1. Ragon BK, Shah MV, D'Souza A, et al. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023;7(12):2746–2757. - PMC - PubMed
    1. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279–3289. - PMC - PubMed
    1. Jones JR, Cairns D, Menzies T, et al. Second primary malignancy incidence in patients receiving lenalidomide at induction and maintenance; long-term follow up of 4358 patients enrolled to the myeloma XI trial. Blood. 2022;140(Supplement 1):1823–1825.
    1. Jonsdottir G, Lund SH, Bjorkholm M, et al. Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. Haematologica. 2016;101(4):e145–e148. - PMC - PubMed
    1. Costa LJ, Godby KN, Chhabra S, Cornell RF, Hari P, Bhatia S. Second primary malignancy after multiple myeloma-population trends and cause-specific mortality. Br J Haematol. 2018;182(4):513–520. - PubMed

MeSH terms